Longitudinal p-tau217 Classification Tracks Alzheimer’s Disease Progression
Personalized briefing
Discovery of the day · Neurology
Longitudinal plasma phosphorylated tau217 classification and the association with Alzheimer’s disease progression
Dear Damien Boorman, this is your personalized scientific intelligence briefing — curated for your work in Neurology.
Key finding
Medicine · Neurology
Discovery of the day
This multi-cohort study of 2,117 individuals establishes that baseline plasma p-tau217 thresholds achieve high and sustained accuracy (86%–95%) for classifying amyloid-β PET positivity over up to five years of follow-up. Longitudinally, most p-tau217-positive individuals remained stable (93%–98%), while those progressing to positive more frequently exhibited Aβ abnormalities and experienced accelerated tau accumulation, hippocampal atrophy, and incident dementia compared to stable-negative profiles. These findings validate longitudinal plasma p-tau217 monitoring as a scalable and reliable tool for risk stratification and disease monitoring in Alzheimer’s disease, directly relevant to your translational work in biomarker-driven neurological research and clinical trial design.
Novelty
85%
Rigor
91%
Significance
92%
Validity
90%
Clarity
88%
Advertisement
GroupRFQ — join group deals on lab & medical equipment. Pool orders, unlock volume pricing. See open deals →
Your briefing is personalized based on your selected fields, keywords, and research interests.
